AR054438A1 - Inhibidores de adn -pk - Google Patents

Inhibidores de adn -pk

Info

Publication number
AR054438A1
AR054438A1 ARP060101479A ARP060101479A AR054438A1 AR 054438 A1 AR054438 A1 AR 054438A1 AR P060101479 A ARP060101479 A AR P060101479A AR P060101479 A ARP060101479 A AR P060101479A AR 054438 A1 AR054438 A1 AR 054438A1
Authority
AR
Argentina
Prior art keywords
optionally substituted
group
alkyl
attached
hydrogen
Prior art date
Application number
ARP060101479A
Other languages
English (en)
Inventor
Cameron Graeme Smith
Niall Morrison Martin
Keith Allan Menear
Marc Geoffrey Hummersone
Xiao Ling Cockcroft
Bernard Thomas Golding
Ian Robert Hardcastle
David Richard Newell
Hilary Alan Calvert
Nicola Jane Curtin
Roger John Griffin
Original Assignee
Kudos Pharm Ltd
Cancer Rec Tech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0507831A external-priority patent/GB0507831D0/en
Application filed by Kudos Pharm Ltd, Cancer Rec Tech Ltd filed Critical Kudos Pharm Ltd
Publication of AR054438A1 publication Critical patent/AR054438A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Abstract

Reivindicacion 1: Un compuesto caracterizado porque es de formula (1) e isomeros, sales, solvatos, formas químicamente protegidas y prodrogas del mismo, donde: A, B y D se seleccionan respectivamente entre el grupo que consiste en (i) CH, NH, C; (ii) CH, N, N; y (ii) CH, O, C; la líneas punteadas representan dos doble enlaces en las ubicaciones apropiadas; RN1 y RN2 se seleccionan en forma independiente entre hidrogeno, un grupo C1-7 alquilo, C3-20 heterociclilo, o C5-20 arilo opcionalmente sustituido, o pueden formar juntos, junto con el átomo de nitrogeno al cual están unidos, un anillo heterocíclico opcionalmente sustituido con entre 4 y 8 átomos del anillo; Z2,Z3, Z4, Z5 y Z6, junto con el átomo de carbono al cual están unidos, forman un anillo aromático; Z2 se selecciona entre el grupo que consiste en CR2, N, NH, S, y O; Z3 es CR3; Z4 se selecciona entre el grupo que consiste en CR4, N, NH, S y O; Z5 es un enlace directo, o se selecciona entre el grupo que consiste en O, N, NH, S y CH; R2 es H; R3 se selecciona entre halo o C5-20 arilo opcionalmente sustituido; R4 se selecciona ente el grupo que consiste en H, OH, NO2 y Q-Y-X, donde Q es -NH-C(=O)- o -O-; Y es un grupo C1-5 alquileno opcionalmente sustituido; X se selecciona entre SRS1 o NRN3RN4, donde, RS1, o RN3 y RN4 se seleccionan en forma independiente entre hidrogeno, grupos C1-7 alquilo, C5-20arilo, o C3-20 heterociclilo opcionalmente sustituidos, o RN3 y RN4 pueden formar juntos, junto con el átomo de nitrogeno al cual están unidos, un anillo heterocíclico opcionalmente sustituido con entre 4 y 8 átomos del anillo; si Q es -O-, X puede seleccionarse además ente -C(=O)-NRN5RN6, donde RN5 y RN6 se seleccionan en forma independiente entre hidrogeno, grupos C1-7 alquilo, C5-20arilo, o C3-20 heterociclilo opcionalmente sustituidos, o RN5 y RN6 pueden formar juntos, junto con el átomo de nitrogeno al cual están unidos, un anillo heterocíclico opcionalmente sustituido con entre 4 y 8 átomos del anillo y si Q es -NH-C(=O)-, -Y-X puede seleccionarse adicionalmente entre C1-7 alquilo. Composiciones farmacéuticas que los contienen y usos como agentes potenciadores de la quimioterapia y de la radioterapia, en el tratamiento del cáncer.
ARP060101479A 2005-04-15 2006-04-12 Inhibidores de adn -pk AR054438A1 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US67188605P 2005-04-15 2005-04-15
US67183005P 2005-04-15 2005-04-15
GB0507831A GB0507831D0 (en) 2005-04-18 2005-04-18 DNA-PK inhibitors
US69606405P 2005-07-01 2005-07-01
US71890405P 2005-09-20 2005-09-20

Publications (1)

Publication Number Publication Date
AR054438A1 true AR054438A1 (es) 2007-06-27

Family

ID=36579227

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP060101480A AR053358A1 (es) 2005-04-15 2006-04-12 Inhibidores de adn - pk
ARP060101479A AR054438A1 (es) 2005-04-15 2006-04-12 Inhibidores de adn -pk

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ARP060101480A AR053358A1 (es) 2005-04-15 2006-04-12 Inhibidores de adn - pk

Country Status (13)

Country Link
US (2) US7696203B2 (es)
EP (2) EP1869021A1 (es)
JP (2) JP2008535903A (es)
KR (1) KR20080002963A (es)
AR (2) AR053358A1 (es)
AU (1) AU2006235731A1 (es)
CA (1) CA2603637A1 (es)
IL (1) IL186445A0 (es)
MX (1) MX2007012696A (es)
NO (1) NO20075809L (es)
TW (2) TW200720274A (es)
UY (1) UY29479A1 (es)
WO (2) WO2006109081A1 (es)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0119865D0 (en) * 2001-08-14 2001-10-10 Cancer Res Campaign Tech DNA-PK inhibitors
MXPA06001599A (es) * 2003-08-13 2006-05-19 Kudos Pharm Ltd Aminopironas y su uso como inhibidores de atm.
CA2580229A1 (en) 2004-09-20 2006-03-30 Kudos Pharmaceuticals Limited Dna-pk inhibitors
TW200638938A (en) * 2005-02-09 2006-11-16 Kudos Pharm Ltd ATM inhibitors
AR053358A1 (es) * 2005-04-15 2007-05-02 Cancer Rec Tech Ltd Inhibidores de adn - pk
UY31232A1 (es) * 2007-07-19 2009-03-02 Compuestos derivados de dibenzotifenilamino-cromen-4-onas activas sustituidas y sus isomeros y aplicaciones
EP2198710A1 (de) 2008-12-19 2010-06-23 Bayer CropScience AG Verwendung von 5-Pyridin-4yl-(1,3)Thiazole zur Bekämpfung phytopathogener Pilze
WO2010136778A1 (en) * 2009-05-29 2010-12-02 Kudos Pharmaceuticals Limited Dibenzothiophene derivatives as dna- pk inhibitors
FR2947548B1 (fr) * 2009-07-02 2012-05-18 Sanofi Aventis Nouveaux derives de 1h-pyrimidin-2-one, leur preparation pharmaceutique comme inhibiteurs de phosphorylation d'akt(pkb)
FR2947551B1 (fr) * 2009-07-02 2012-05-18 Sanofi Aventis Nouveaux derives de 1,2,3,4-tetrahydro-pyrimido{1,2-a)pyrimidin-6-one, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de phosphorylation d'akt (pkb)
RS53317B (en) 2009-07-02 2014-10-31 Sanofi NEW DERIVATIVES (6-OXO-1,6-DIHYDROPYRIMIDIN-2-IL) AMIDES, THEIR PRODUCTION AND THEIR PHARMACEUTICAL USE AS AKT PHOSPHORILATION INHIBITOR
FR2947550B1 (fr) * 2009-07-02 2012-05-18 Sanofi Aventis Nouveaux derives de 2,3-dihydro-1h-imidazo{1,2-a}pyrimidin-5-one, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de phosphorylation d'akt (pkb)
FR2951170B1 (fr) * 2009-10-09 2011-12-02 Sanofi Aventis Nouveaux derives de 1h-pyrimidin-2-one, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de phosphorylation d'akt(pkb)
EP2448939B1 (fr) * 2009-07-02 2017-03-01 Sanofi Derives de 2,3-dihydro-1h-imidazo {1,2-a} pyrimidin-5-one, leur preparation et leur utilisation pharmaceutique
BRPI1015943A8 (pt) * 2009-07-02 2018-01-09 Sanofi Sa derivados de 1,2,3,4-tetra - hidro - pirimido {1,2-a} pirimidin-6-ona, o respectivo preparo e a respectiva utilização farmacêutica.
WO2011001115A1 (fr) 2009-07-02 2011-01-06 Sanofi-Aventis Nouveaux derives de 6-morpholin-4-yl-pyrimidin-4- ( 3h ) -one, leur preparation pharmaceutique comme inhibiteurs de phos phorylat i on d ' akt ( pkb )
US8399460B2 (en) * 2009-10-27 2013-03-19 Astrazeneca Ab Chromenone derivatives
US9618663B2 (en) 2010-04-15 2017-04-11 3M Innovative Properties Company Retroreflective articles including optically active areas and optically inactive areas
US20130109687A1 (en) * 2010-04-30 2013-05-02 Gary J. Nabel Methods of treating hiv infection: inhibition of dna dependent protein kinase
DE102010035744A1 (de) 2010-08-28 2012-03-01 Merck Patent Gmbh Imidazolonylchinoline
HUE024504T2 (en) 2010-12-23 2016-01-28 Sanofi Sa Pyrimidine derivatives, a process for their preparation and their use in medicine
HUE030393T2 (en) 2010-12-28 2017-05-29 Sanofi Sa New pyrimidine derivatives, a process for their preparation, and their pharmaceutical use as inhibitors of AKT (PKB) phosphorylation
UY34013A (es) * 2011-04-13 2012-11-30 Astrazeneca Ab ?compuestos de cromenona con actividad anti-tumoral?.
CN106986863B (zh) 2012-04-24 2019-12-31 沃泰克斯药物股份有限公司 Dna-pk抑制剂
BR112014031292A2 (pt) * 2012-06-15 2017-06-27 Basf Se sistema cristalino de múltiplos componentes, processo para obter a composição cristalina, e, composição farmacêutica
FR2992314B1 (fr) 2012-06-22 2015-10-16 Sanofi Sa Nouveaux derives de 2,3-dihydro-1h-imidazo{1,2-a}pyrimidin-5-one et 1,2,3,4-tetrahydro-pyrimido{1,2-a}pyrimidin-6-one comportant une morpholine substituee, leur preparation et leur utilisation pharmaceutique
FR2992316A1 (fr) 2012-06-22 2013-12-27 Sanofi Sa Derives de pyrimidinones, leur preparation et leur application en therapeutique
CN105246883B (zh) 2013-03-12 2017-07-21 沃泰克斯药物股份有限公司 Dna‑pk抑制剂
WO2016086261A1 (en) 2014-12-02 2016-06-09 Prana Biotechnology Limited 4H-PYRIDO[1,2-a]PYRIMIDIN-4-ONE COMPOUNDS
US11110108B2 (en) 2016-09-27 2021-09-07 Vertex Pharmaceuticals Incorporated Method for treating cancer using a combination of DNA-damaging agents and DNA-PK inhibitors
CN109232476B (zh) * 2018-11-06 2020-06-26 常州大学 一种制备n-苯基-3-吗啡啉丙酰胺的方法
US20230111712A1 (en) * 2020-03-13 2023-04-13 Arizona Board Of Regents On Behalf Of The University Of Arizona Stable reactive compositions for bioconjugation, probes, and protein labeling

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1303724A (es) 1969-05-14 1973-01-17
JPH0753725B2 (ja) * 1987-10-08 1995-06-07 富山化学工業株式会社 ４ｈ―１―ベンゾピラン―４―オン誘導体およびその塩、それらの製造法並びにそれらを含有する抗炎症剤
US5284856A (en) * 1988-10-28 1994-02-08 Hoechst Aktiengesellschaft Oncogene-encoded kinases inhibition using 4-H-1-benzopyran-4-one derivatives
JPH04502322A (ja) 1988-12-21 1992-04-23 ジ・アップジョン・カンパニー 抗アテローム性動脈硬化症性および抗血栓性１―ベンゾピラン―４―オン類および２―アミノ―１，３―ベンゾオキサジン―４―オン類
US5703075A (en) 1988-12-21 1997-12-30 Pharmacia & Upjohn Company Antiatherosclerotic and antithrombotic 1-benzopyran-4-ones and 2-amino-1,3-benzoxazine-4-ones
JPH03215423A (ja) 1990-01-18 1991-09-20 Kyowa Hakko Kogyo Co Ltd 血管拡張剤
CA2081577A1 (en) 1990-06-20 1991-12-21 Ronald B. Gammill Antiatherosclerotic and antithrombotic 1-benzopyran-4-ones and 2-amino-1, 3-benzoxazine-4-ones
ATE128128T1 (de) 1990-06-29 1995-10-15 Upjohn Co Antiatherosclerotische und antithrombotische 2- amino-6-phenyl-4h-pyran-4-one.
US5252735A (en) 1990-06-29 1993-10-12 The Upjohn Company Antiatherosclerotic and antithrombotic 2-amino-6-phenyl-4H-pyran-4-ones
US5302613A (en) * 1990-06-29 1994-04-12 The Upjohn Company Antiatheroscleroic and antithrombotic 2-amino-6-phenyl-4H-pyran-4-ones
EP0610519B1 (en) 1992-09-02 1999-12-01 Kyowa Hakko Kogyo Co., Ltd. Anti-hiv drug
US5922755A (en) * 1993-04-09 1999-07-13 Toyama Chemical Co., Ltd. Immunomodulator, cell adhesion inhibtor, and agent for treating, and preventing autoimmune diseases
US5378725A (en) 1993-07-19 1995-01-03 The Arizona Board Of Regents Inhibition of phosphatidylinositol 3-kinase with wortmannin and analogs thereof
US5441947A (en) 1993-08-25 1995-08-15 Eli Lilly And Company Methods of inhibiting vascular restenosis
US5504103A (en) 1993-08-25 1996-04-02 Eli Lilly And Company Inhibition of phosphatidylinositol 3-kinase with 17 β-hydroxywortmannin and analogs thereof
US5468773A (en) 1993-08-25 1995-11-21 Eli Lilly And Company Methods for inhibiting bone loss and cartilage degradation using wortmannin and its analogs
CA2133815A1 (en) 1993-10-12 1995-04-13 Jeffrey Alan Dodge Inhibition of phosphatidylinositol 3-kinase with viridin, demethoxyviridin, viridiol, demethoxyviridiol, virone, wortmannolone, and analogs thereof
US6632789B1 (en) 1994-04-29 2003-10-14 The United States Of America As Represented By The Secretary Of The Navy Methods for modulating T cell responses by manipulating intracellular signal transduction
US5480906A (en) 1994-07-01 1996-01-02 Eli Lilly And Company Stereochemical Wortmannin derivatives
GB9521987D0 (en) 1995-10-26 1996-01-03 Ludwig Inst Cancer Res Phosphoinositide 3-kinase modulators
US5733920A (en) * 1995-10-31 1998-03-31 Mitotix, Inc. Inhibitors of cyclin dependent kinases
AU1461197A (en) 1995-11-16 1997-06-05 Icos Corporation Cell cycle checkpoint pik-related kinase materials and methods
GB2302021A (en) 1996-10-16 1997-01-08 Lilly Co Eli Inhibiting bone loss or resorption
CA2292540A1 (en) 1997-06-06 1998-12-10 Jann N. Sarkaria Screening for phosphatidylinositol related-kinase inhibitors
AU8068198A (en) 1997-06-13 1998-12-30 President And Fellows Of Harvard College Methods for treating human cancers
FR2776291B1 (fr) 1998-03-18 2000-06-16 Pf Medicament Nouveaux derives bis-benzamides, leur procede de fabrication, les compositions pharmaceutiques les contenant et leur utilisation comme medicament
US6387640B1 (en) * 1999-02-10 2002-05-14 St. Jude Children's Research Hospital ATM kinase modulation for screening and therapies
US6348311B1 (en) * 1999-02-10 2002-02-19 St. Jude Childre's Research Hospital ATM kinase modulation for screening and therapies
US6333180B1 (en) * 1999-12-21 2001-12-25 International Flavors & Fragrances Inc. Bioprocess for the high-yield production of food flavor-acceptable jasmonic acid and methyl jasmonate
EP1257537B1 (en) * 2000-01-24 2007-05-30 AstraZeneca AB Therapeutic morpholino-substituted compounds
KR20080015888A (ko) 2000-06-28 2008-02-20 테바 파마슈티컬 인더스트리즈 리미티드 카르베딜올
US7179912B2 (en) 2000-09-01 2007-02-20 Icos Corporation Materials and methods to potentiate cancer treatment
EP1353693B1 (en) 2001-01-16 2005-03-16 Glaxo Group Limited Pharmaceutical combination containing a 4-quinazolineamine and paclitaxel, carboplatin or vinorelbine for the treatment of cancer
GB0119865D0 (en) * 2001-08-14 2001-10-10 Cancer Res Campaign Tech DNA-PK inhibitors
GB0119863D0 (en) 2001-08-14 2001-10-10 Cancer Res Campaign Tech DNA-PK inhibitors
WO2003034997A2 (en) 2001-10-24 2003-05-01 Iconix Pharmaceuticals, Inc. Modulators of phosphoinositide 3-kinase
WO2003035618A2 (en) 2001-10-24 2003-05-01 Iconix Pharmaceuticals, Inc. Modulators of phosphoinositide 3-kinase
EP2174939A1 (en) 2002-02-25 2010-04-14 Kudos Pharmaceuticals Limited Pyranones useful as ATM inhibitors
US7049313B2 (en) * 2002-02-25 2006-05-23 Kudos Pharmaceuticals Ltd. ATM inhibitors
JP4500161B2 (ja) 2002-04-30 2010-07-14 クドス ファーマシューティカルズ リミテッド フタラジノン誘導体
MXPA06001599A (es) 2003-08-13 2006-05-19 Kudos Pharm Ltd Aminopironas y su uso como inhibidores de atm.
CA2580229A1 (en) 2004-09-20 2006-03-30 Kudos Pharmaceuticals Limited Dna-pk inhibitors
TW200638938A (en) 2005-02-09 2006-11-16 Kudos Pharm Ltd ATM inhibitors
AR053358A1 (es) * 2005-04-15 2007-05-02 Cancer Rec Tech Ltd Inhibidores de adn - pk
UY31232A1 (es) 2007-07-19 2009-03-02 Compuestos derivados de dibenzotifenilamino-cromen-4-onas activas sustituidas y sus isomeros y aplicaciones

Also Published As

Publication number Publication date
EP1869021A1 (en) 2007-12-26
US7696203B2 (en) 2010-04-13
KR20080002963A (ko) 2008-01-04
WO2006109084A1 (en) 2006-10-19
JP2008535902A (ja) 2008-09-04
WO2006109081A1 (en) 2006-10-19
TW200720274A (en) 2007-06-01
AR053358A1 (es) 2007-05-02
US20060264427A1 (en) 2006-11-23
IL186445A0 (en) 2008-01-20
TW200720271A (en) 2007-06-01
EP1869040A1 (en) 2007-12-26
NO20075809L (no) 2007-12-27
JP2008535903A (ja) 2008-09-04
MX2007012696A (es) 2008-03-14
CA2603637A1 (en) 2006-10-19
AU2006235731A1 (en) 2006-10-19
UY29479A1 (es) 2006-11-30
US20060264623A1 (en) 2006-11-23

Similar Documents

Publication Publication Date Title
AR054438A1 (es) Inhibidores de adn -pk
CR11546A (es) Derivados de carboxamidas azabiciclicas, su preparacion y su aplicacion en terapeutica
MA32711B1 (fr) Pyrrolidine-2-carboxamides substitues
TW200738706A (en) Pyrido-, pyrazo-and pyrimido-pyrimidine derivatives and their use as mTOR inhibitors
ECSP099728A (es) Compuestos amino-heterocíclicos
NI200700102A (es) Derivados de indol tetraciclicos como agentes antiviricos
AR048039A1 (es) Profarmacos de piperazina y agentes antivirales de piperidina sustituidos
EA200702080A1 (ru) Полициклическое карбомоилпиридоновое производное, обладающее ингибиторной активностью в отношении интегразы вич
AR062056A1 (es) Derivados heterociclicos fusionados y metodos de uso
PE20060531A1 (es) Derivados de piridazin-3-(2h)-ona como inhibidores de la fosfodiesterasa 4
AR053436A1 (es) Iderivados de 3-(indazol-5-il)-(1,2,4)triazina inhibidores de quinasas
CO6270320A2 (es) Derivados de piperidina utiles como antagonistas del receptor orexina
CR10712A (es) Derivados de quinazolinona 5-sustituidos como agentes antitumorales
DOP2010000046A (es) Compuestos de biciclolactama sustituida
AR059314A1 (es) Derivados de las benzamidas y heteroarenos
PE20060459A1 (es) DERIVADOS DE AMINO-5,5-DIFENILIMIDAZOLONA COMO INHIBIDORES DE LA ß-SECRETASA
PA8546601A1 (es) Nuevos derivados de indol con afinidad por el receptor 5-ht6
PE20170775A1 (es) Derivados de benzodiazepina citotoxicos
TW200718422A (en) 1,6-Dihydro-1,3,5,6-tetraaza-as-indacene based tricyclic compounds and pharmaceutical compositions comprising same
MA37142A3 (fr) Dérivés de dihydro-benzo-oxazine et de dihydro-pyrido-oxazine
ECSP045073A (es) Nuevos derivados de piperazina
CR8288A (es) 6-[ (sustituido) fenil] triazolopirimidinas como agentes anticancer
DOP2010000022A (es) Derivados de pirimidina 934
AR054102A1 (es) Derivados de fenil-piperazina-metanona. procesos de obtencion y composiciones farmaceuticas
MX2009009466A (es) Compuestos triciclicos de utilidad en el tratamiento de trastornos del hierro.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal